APA (7th ed.) Citation

X, L., J, W., S, L., J, F., Y, H., C, X., . . . X, W. (2025). Pyrotinib inhibits the tumorigenicity of HER2-positive non-small cell lung cancer by inducing ARIH1/ubiquitin/lysosome-dependent degradation of HER2. Cellular oncology (Dordrecht, Netherlands), 48(6), 1795. https://doi.org/10.1007/s13402-025-01107-z

Chicago Style (17th ed.) Citation

X, Li, et al. "Pyrotinib Inhibits the Tumorigenicity of HER2-positive Non-small Cell Lung Cancer by Inducing ARIH1/ubiquitin/lysosome-dependent Degradation of HER2." Cellular Oncology (Dordrecht, Netherlands) 48, no. 6 (2025): 1795. https://doi.org/10.1007/s13402-025-01107-z.

MLA (9th ed.) Citation

X, Li, et al. "Pyrotinib Inhibits the Tumorigenicity of HER2-positive Non-small Cell Lung Cancer by Inducing ARIH1/ubiquitin/lysosome-dependent Degradation of HER2." Cellular Oncology (Dordrecht, Netherlands), vol. 48, no. 6, 2025, p. 1795, https://doi.org/10.1007/s13402-025-01107-z.